Kintor Pharmaceutical Limited Stock Net Income
| KNTPF Stock | USD 0.33 0.02 5.71% |
As of the 15th of February 2026, Kintor Pharmaceutical secures the Standard Deviation of 4.75, risk adjusted performance of 0.0777, and Mean Deviation of 1.51. Kintor Pharmaceutical Limited technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Kintor Pharmaceutical risk adjusted performance, variance, as well as the relationship between the Variance and kurtosis to decide if Kintor Pharmaceutical Limited is priced some-what accurately, providing market reflects its recent price of 0.33 per share. As Kintor Pharmaceutical appears to be a penny stock we also strongly suggest to check its information ratio numbers.
Kintor Pharmaceutical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Kintor Pharmaceutical's valuation are provided below:Kintor Pharmaceutical Limited does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Kintor |
Kintor Pharmaceutical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Kintor Pharmaceutical's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Kintor Pharmaceutical.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Kintor Pharmaceutical on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Kintor Pharmaceutical Limited or generate 0.0% return on investment in Kintor Pharmaceutical over 90 days. Kintor Pharmaceutical is related to or competes with Paradigm Biopharmaceutica, Nuo Therapeutics, Hofseth BioCare, Imugene, Satellos Bioscience, Scancell Holdings, and Shield Therapeutics. Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipel... More
Kintor Pharmaceutical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Kintor Pharmaceutical's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Kintor Pharmaceutical Limited upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0713 | |||
| Maximum Drawdown | 32.99 |
Kintor Pharmaceutical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kintor Pharmaceutical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Kintor Pharmaceutical's standard deviation. In reality, there are many statistical measures that can use Kintor Pharmaceutical historical prices to predict the future Kintor Pharmaceutical's volatility.| Risk Adjusted Performance | 0.0777 | |||
| Jensen Alpha | 0.3733 | |||
| Total Risk Alpha | 0.0459 | |||
| Treynor Ratio | 0.9514 |
Kintor Pharmaceutical February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0777 | |||
| Market Risk Adjusted Performance | 0.9614 | |||
| Mean Deviation | 1.51 | |||
| Coefficient Of Variation | 1161.91 | |||
| Standard Deviation | 4.75 | |||
| Variance | 22.52 | |||
| Information Ratio | 0.0713 | |||
| Jensen Alpha | 0.3733 | |||
| Total Risk Alpha | 0.0459 | |||
| Treynor Ratio | 0.9514 | |||
| Maximum Drawdown | 32.99 | |||
| Skewness | 2.65 | |||
| Kurtosis | 21.61 |
Kintor Pharmaceutical Backtested Returns
Kintor Pharmaceutical appears to be out of control, given 3 months investment horizon. Kintor Pharmaceutical has Sharpe Ratio of 0.0867, which conveys that the firm had a 0.0867 % return per unit of risk over the last 3 months. We have found eighteen technical indicators for Kintor Pharmaceutical, which you can use to evaluate the volatility of the firm. Please exercise Kintor Pharmaceutical's Mean Deviation of 1.51, risk adjusted performance of 0.0777, and Standard Deviation of 4.75 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Kintor Pharmaceutical holds a performance score of 6. The company secures a Beta (Market Risk) of 0.42, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Kintor Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Kintor Pharmaceutical is expected to be smaller as well. Please check Kintor Pharmaceutical's information ratio and rate of daily change , to make a quick decision on whether Kintor Pharmaceutical's current price movements will revert.
Auto-correlation | -0.7 |
Very good reverse predictability
Kintor Pharmaceutical Limited has very good reverse predictability. Overlapping area represents the amount of predictability between Kintor Pharmaceutical time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Kintor Pharmaceutical price movement. The serial correlation of -0.7 indicates that around 70.0% of current Kintor Pharmaceutical price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.7 | |
| Spearman Rank Test | 0.02 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Kintor Pharmaceutical Limited reported net income of (842.1 Million). This is 346.74% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The net income for all United States stocks is significantly higher than that of the company.
Kintor Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kintor Pharmaceutical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kintor Pharmaceutical could also be used in its relative valuation, which is a method of valuing Kintor Pharmaceutical by comparing valuation metrics of similar companies.Kintor Pharmaceutical is currently under evaluation in net income category among its peers.
Kintor Fundamentals
| Return On Equity | -0.62 | |||
| Return On Asset | -0.31 | |||
| Operating Margin | (30.26) % | |||
| Current Valuation | 692.39 M | |||
| Shares Outstanding | 447.5 M | |||
| Shares Owned By Insiders | 31.95 % | |||
| Shares Owned By Institutions | 8.41 % | |||
| Price To Book | 5.15 X | |||
| Price To Sales | 17.86 X | |||
| Revenue | 34.23 M | |||
| Gross Profit | 34.23 M | |||
| EBITDA | (833.82 M) | |||
| Net Income | (842.1 M) | |||
| Cash And Equivalents | 387.49 M | |||
| Cash Per Share | 1.00 X | |||
| Total Debt | 147.5 M | |||
| Debt To Equity | 0.20 % | |||
| Current Ratio | 3.44 X | |||
| Book Value Per Share | 3.06 X | |||
| Cash Flow From Operations | (1.05 B) | |||
| Earnings Per Share | (0.35) X | |||
| Number Of Employees | 328 | |||
| Beta | -0.19 | |||
| Market Capitalization | 626.5 M | |||
| Total Asset | 2.07 B | |||
| Z Score | 2.4 | |||
| Net Asset | 2.07 B |
About Kintor Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kintor Pharmaceutical Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kintor Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kintor Pharmaceutical Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Kintor Pink Sheet
Kintor Pharmaceutical financial ratios help investors to determine whether Kintor Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kintor with respect to the benefits of owning Kintor Pharmaceutical security.